Search results for "CIRRHOSIS"

showing 10 items of 964 documents

FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage

2020

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular complications. We examined whether liver fibrosis, diagnosed by FibroScan® , correlates with chronic vascular complications in a cohort of T2DM. METHODS: We recruited 394 outpatients with T2DM attending five Italian diabetes centres who underwent liver ultrasonography (US), FibroScan® and extensive evaluation of macrovascular and microvascular diabetic complications. RESULTS: Steatosis by US was present in 89%. Almost all patients (96%) were on hypoglycaemic drugs, 58% had at least one chronic vascular complication,…

Liver CirrhosisNonalcoholic steatohepatitismedicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseFibrosisGastroenterologydigestive system diseasesNASH FIBROSCAN CARDIOVASCULARLiverNon-alcoholic Fatty Liver DiseaseFibrosiscardiovascular diseaseInternal medicineNAFLDNonalcoholic fatty liver diseasemedicineElasticity Imaging TechniquesHumanstype 2 diabetesbusinessliver stiffness measurementmicrovascular complication
researchProduct

Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis

2022

Background: The aims of this study were to quantify the histological improvement and its risk factors in patients with NASH enrolled in the placebo arms of randomized controlled trials (RCTs), and to indirectly compare the effect of several investigational drugs for NASH on validated histological outcomes.Data synthesis: A comprehensive search was conducted to detect phase 2 and 3 RCTs comparing pharmacological interventions in patients with NASH. According to Food and Drug Administra-tion (FDA) recommendations, primary outcomes included: 1) NASH resolution without wors-ening of fibrosis; 2) At least 1-point reduction in fibrosis without worsening of NASH. Meta -analysis and meta-regression…

Liver CirrhosisNutrition and DieteticsLiverNon-alcoholic Fatty Liver DiseaseEndocrinology Diabetes and MetabolismNetwork Meta-AnalysisMeta-analysis NASH Network meta-analysisMedicine (miscellaneous)HumansVitamin EDrugs InvestigationalCardiology and Cardiovascular MedicineRandomized Controlled Trials as Topic
researchProduct

Fever and rhomboid target lesion in decompensated cirrhosis

2012

A 53-year-old woman with Child-Pugh B, hepatitis C virus-related cirrhosis presented with a 3 day history of high fever (peak 39·5°C) and a non-itchy rash. On admission, physical examination showed mild ascites, and a temperature of 38·5°C, a pulse rate of 88 beats per min, and a respiratory rate of 18 breaths per min were recorded. Many large (about 15 cm diameter) target lesions were present on the patient’s trunk and arms and legs, seen as concentric rings of a dull red, pink, or violet colour surrounding a clear centre (fi gure). No mucosal lesions were noted. Laboratory tests recorded a white-blood-cell count of 12×109 cells per L and a C-reactive protein concentration of 3·4 mg/L. Abd…

Liver CirrhosisOfloxacinmedicine.medical_specialtyCirrhosisFeverErysipelothrix rhusiopathiae cirrhosisPhysical examinationErysipelothrix rhusiopathiaeGastroenterologyErysipelothrix InfectionsLiver diseaseInternal medicineAscitesHumansMedicineEndocarditisbiologymedicine.diagnostic_testbusiness.industryHepatitis CExanthemaMiddle AgedHepatologybiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsSurgeryInfectious DiseasesFever Liver CirrhosisErysipelothrixFemalemedicine.symptombusiness
researchProduct

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.

2010

A genome-wide association screen for primary biliary cirrhosis risk alleles was performed in an Italian cohort. The results from the Italian cohort replicated IL12A and IL12RB associations, and a combined meta-analysis using a Canadian dataset identified newly associated loci at SPIB (P = 7.9 × 10−11, odds ratio (OR) = 1.46), IRF5-TNPO3 (P = 2.8 × 10−10, OR = 1.63) and 17q12-21 (P = 1.7 × 10−10, OR = 1.38).

Liver CirrhosisOncologyCanadamedicine.medical_specialtyCirrhosisEuropean Continental Ancestry GroupLOCIPRIMARY BILIARY CIRRHOSIS; GENOME WIDE ASSOCIATION; LOCIGenome-wide association studyLocus (genetics)genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver CirrhosiBiologyBiliary Meta-Analysis as Topic Odds RatioWhite PeopleArticleGENOME WIDE ASSOCIATIONAlleles Canada European Continental Ancestry Groupprimary biliary cirrhosiPrimary biliary cirrhosisMeta-Analysis as TopicMED/12 - GASTROENTEROLOGIAIL12AInternal medicineOdds RatioGeneticsmedicineHumansAllelegenomeAlleles Canada European Continental Ancestry Group; genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver Cirrhosis; Biliary Meta-Analysis as Topic Odds RatioAllelesprimary biliary cirrhosis genome-wide meta-analysesGeneticsLiver Cirrhosis BiliaryBiliaryOdds ratiomedicine.diseasePrimary biliary cirrhosisInterferon Regulatory FactorsCohortGenome-Wide Association Study
researchProduct

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

2012

Hepatitis C virus (HCV) is the leading cause of liver transplantation in Europe and is associated with an increased risk of hepatocellular carcinoma (HCC). Because of the chronic nature of the disease, estimates suggest that the burden on healthcare will increase dramatically for this entity. Clinical care of patients with HCV-related liver disease has advanced considerably in the last two decades, thanks to increasing knowledge about the mechanisms of the disease, development of diagnostic procedures, and advances in therapeutic and preventive approaches. HCV RNA testing, HCV genotyping and staging of liver disease are essential for the diagnosis and the management of HCV therapy. Furtherm…

Liver CirrhosisOncologymedicine.medical_specialtyGenotypemedicine.medical_treatmentHepatitis C virusHepacivirusDiseaseLiver transplantationmedicine.disease_causeAntiviral AgentsPolyethylene GlycolsLiver diseasechemistry.chemical_compoundPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesStandard of CareHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical PracticechemistryHepatocellular carcinomaPractice Guidelines as TopicImmunologyRNA ViralDrug Therapy Combinationbusinessmedicine.drugLiver International
researchProduct

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

2020

© 2020 The Author(s).

Liver CirrhosisPROGNOSISCirrhosisSCORING SYSTEM[SDV]Life Sciences [q-bio]PROGRESSIONDiseaseBiomarker Cirrhosis NAFLD NASHSTEATOHEPATITISDEFINITIONSCohort Studies0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasePharmacology (medical)030212 general & internal medicineLongitudinal StudiesRegistriesComputingMilieux_MISCELLANEOUSmedia_commonPharmacology. TherapyFatty liverLiver NeoplasmsNASHGeneral Medicine3. Good healthCirrhosisLiver317 PharmacyCohort0305 other medical scienceCohort studymedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAGeriatrikQUESTIONNAIRENAFLD; NASH; Cirrhosis; Biomarker610 Medicine & health03 medical and health sciencesNAFLDmedicineSTEATOSISmedia_common.cataloged_instanceHumansALGORITHMEuropean unionIntensive care medicine030505 public healthbusiness.industryCONSUMPTIONBiomarkerSTAGING SYSTEMmedicine.diseaseDiabetes Mellitus Type 2Geriatrics3121 General medicine internal medicine and other clinical medicine3111 BiomedicineHuman medicineSteatohepatitisbusinessBiomarker; Cirrhosis; NAFLD; NASH
researchProduct

StellaTUM: current consensus and discussion on pancreatic stellate cell research

2011

The field of pancreatic stellate cell (PSC) biology is very young, as the essential in-vitro tools to study these cells (ie, methods to isolate and culture PSC) were only developed as recently as in 1998. Nonetheless, there has been an exponential increase in research output in this field over the past decade, with numerous research groups around the world focusing their energies into elucidating the biology and function of these cells. It is now well established that PSC are responsible for producing the stromal reaction (fibrosis) of two major diseases of the pancreas—chronic pancreatitis and pancreatic cancer. Despite exponentially increasing data, the methods for studying PSC remain var…

Liver CirrhosisPathologycell migrationpancreatic cancerCellpancreatitisPancreatic stellate cellLeading Articlehepatic surgerycell biologymolecular biologyhepatic fibrosis1506pancreaspancreatic surgerysignallinghepatic stellate cellalcoholPancreatic Stellate CellsGastroenterologypancreatic functionddc:medicine.anatomical_structurePancreaspancreatic fibrosissignal transductionstellate cellsmedicine.medical_specialtyStromal cellacute pancreatitisextracellular matrixadjuvant treatmentAbdominal surgerycancer geneticsliverpancreatic enzymesdigestive systemchronic pancreatitisstem cellsPancreatitis ChronicPancreatic cancermedicinecancerHumansRegenerationpancreatic physiologyendoscopyProgenitor cellmarkeradenocarcinomaHelicobacter pyloribusiness.industryfibrosisPancreatic Diseasesmedicine.diseaseexperimental pancreatitisLiver RegenerationPancreatic Neoplasmspancreatic pathologyconsensusCancer cellgene expressionHepatic stellate cellbusinesspancreatic diseaseGut
researchProduct

Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma.

1994

Hepatocellular carcinoma is one of the most common human cancers with an annual incidence of about 1,000,000 cases worldwide. Although hepatocellular carcinoma is predominant in hepatitis B virus endemic areas, it has also become a major problem in Europe, Japan and North America in close association with the increasing incidence of hepatitis C virus infection. The pathogenetic role of hepatitis C virus infection in the development of HBsAg-negative hepatocellular carcinoma needs to be clarified. In this paper the case of a 66-year-old HBsAg-negative and anti-HCV positive female who developed hepatocellular carcinoma in a cirrhotic liver is reported. After 1 year of follow up, urgent laparo…

Liver CirrhosisPathologymedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusHepacivirusOvaryHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologyVirusMetastasisFlaviviridaeInternal medicinemedicineHumansAgedHepatitis B virusOvarian NeoplasmsHepatitis B Surface AntigensHepatologybiologyIncidenceLiver Neoplasmsmedicine.diseasebiology.organism_classificationdigestive system diseasesmedicine.anatomical_structureHepatocellular carcinomaRNA ViralFemaleTomography X-Ray ComputedJournal of hepatology
researchProduct

Evolving therapies for liver fibrosis

2013

Fibrosis is an intrinsic response to chronic injury, maintaining organ integrity when extensive necrosis or apoptosis occurs. With protracted damage, fibrosis can progress toward excessive scarring and organ failure, as in liver cirrhosis. To date, antifibrotic treatment of fibrosis represents an unconquered area for drug development, with enormous potential but also high risks. Preclinical research has yielded numerous targets for antifibrotic agents, some of which have entered early-phase clinical studies, but progress has been hampered due to the relative lack of sensitive and specific biomarkers to measure fibrosis progression or reversal. Here we focus on antifibrotic approaches for li…

Liver CirrhosisPathologymedicine.medical_specialtyCirrhosisT-LymphocytesInflammationApoptosisBioinformaticsMonocytesMiceFibrosismedicineHepatic Stellate CellsAnimalsHumansMyofibroblastsInflammationWound Healingbusiness.industryLiver DiseasesMacrophagesStem CellsReview SeriesGeneral Medicinemedicine.diseaseFibrosisClinical trialDrug developmentLiverHepatic stellate cellDisease ProgressionHepatocytesStem cellmedicine.symptombusinessWound healingBiomarkers
researchProduct

Cirrhosis: CT and MR imaging evaluation

2006

In this article, we present the CT and MR imaging characteristics of the cirrhotic liver. We describe the altered liver morphology in different forms of viral, alcoholic and autoimmune end-stage liver disease. We present the spectrum of imaging findings in portal hypertension, such as splenomegaly, ascites and varices. We describe the patchy and lacelike patterns of fibrosis, along with the focal confluent form. The process of hepatocarcinogenesis is detailed, from regenerative to dysplastic nodules to overt hepatocellular carcinoma. Different types of non-neoplastic focal liver lesions occurring in the cirrhotic liver are discussed, including arterially enhancing nodules, hemangiomas and p…

Liver CirrhosisPathologymedicine.medical_specialtyCirrhosisbusiness.industryGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingLiver diseaseLiverHepatocellular carcinomaPractice Guidelines as TopicAscitesBudd–Chiari syndromemedicineHumansPortal hypertensionCongenital hepatic fibrosisRadiology Nuclear Medicine and imagingRadiologyPractice Patterns Physicians'medicine.symptomTomography X-Ray ComputedbusinessHepatic fibrosisEuropean Journal of Radiology
researchProduct